The results further undermine Relvar Ellipta, which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair ...

GSK plc GSK reported fourth-quarter 2024 core ... the upside was primarily driven by solid sales growth of asthma inhaler Trelegy Ellipta across all regions. This was partially offset by the ...

After some disappointing earlier results for GSK’s new asthma treatment Revlar Ellipta, the company has today announced some encouraging news. An open-label non-inferiority lung function study ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... It launched Trelegy Ellipta, the countrys first single inhaler triple therapy (SITT) for ...

They include semaglutide, sold as Ozempic, Wegovy and Rybelsus by Novo Nordisk, Pfizer cancer drugs Ibrance and Xtandi and asthma drug Trelegy Ellipta from GSK. The list of 15 adds to an initial round ...